Emil is a Principal based in ADL’s San Francisco office and a member of our Healthcare & Life Sciences practice.
Prior to ADL, 15+ years of experience in life sciences with a focus on global pricing, value, and market access (PVA) as a strategy consultant (Avalere, Monitor-Deloitte, IQVIA, Dedham), and in industry (Gilead Sciences)
Specifically, Emil’s key areas of expertise encompass global product commercialization / launch / pricing /  contracting strategy development and execution, pro- and retrospective financial analysis, financial modeling and valuation, value-based care business & deal / contract models, and US and international health policy analysis 
He has extensive expertise across 15+ therapeutic areas including oncology, CNS, antivirals, and rheumatology
Particular milestones in Emil’s career include leading Gilead’s global pricing and contracting strategy team for 12+ in-line products in the HIV and Hepatitis C spaces, launching 3 new drugs including the now #1 selling HIV drug Biktarvy, and devising global pricing and contracting strategies for novel cancer drug modalities (i.e., CAR-Ts) Emil earned his BBA from the George Washington University and his MBA from the Columbia School of Business